Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Buy" from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has received a consensus rating of "Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $66.67.

TARS has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a research report on Tuesday, May 27th. Guggenheim boosted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Oppenheimer started coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target on the stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth $25,000. GF Fund Management CO. LTD. bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $44,000. Amalgamated Bank lifted its stake in shares of Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after acquiring an additional 295 shares during the last quarter. Quarry LP bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $166,000. Finally, AlphaQuest LLC bought a new position in shares of Tarsus Pharmaceuticals in the 1st quarter valued at $189,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Stock Down 2.4%

Shares of Tarsus Pharmaceuticals stock traded down $1.00 during trading on Friday, reaching $40.53. The stock had a trading volume of 350,833 shares, compared to its average volume of 685,378. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -14.79 and a beta of 0.80. The stock has a fifty day moving average price of $42.23 and a two-hundred day moving average price of $46.87. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a current ratio of 5.57, a quick ratio of 5.54 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. Sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.